This study investigated the expression alteration and prognostic significance of CCL2 in GBM, and also assessed the predictive value of CCL2 in immunotherapy response, in an attempt to provide relevant theoretical basis for the prognosis and immunotherapy of this highly heterogeneous and fatal brain cancer. This evidence concerns the gene CCL2 and glioblastoma.